US 12,224,049 B2
Systems and methods for monitoring and managing neurological diseases and conditions
Rachel Kuperman, Piedmont, CA (US); Parth Amin, Cary, NC (US); and Bikramjit Sarkar, San Diego, CA (US)
Assigned to Eysz, Inc., Berkeley, CA (US)
Filed by Eysz, Inc., Berkeley, CA (US)
Filed on Dec. 8, 2021, as Appl. No. 17/643,363.
Claims priority of provisional application 63/123,402, filed on Dec. 9, 2020.
Prior Publication US 2022/0180993 A1, Jun. 9, 2022
Int. Cl. G16H 20/10 (2018.01); G16H 40/63 (2018.01)
CPC G16H 20/10 (2018.01) [G16H 40/63 (2018.01)] 20 Claims
OG exemplary drawing
 
1. A computer-implemented method for monitoring a patient having a neurological disease or condition, the method comprising:
receiving, from one or more patient monitoring devices configured to produce eye movement data, first patient data for a baseline time period before the patient has started taking medication for the neurological disease or condition;
determining, based on the first patient data, first seizure data and first side effect data during the baseline time period;
receiving, from the one or more patient monitoring devices, second patient data for a treatment time period in which the patient is taking the medication;
determining, based on the second patient data, second seizure data and second side effect data during the treatment time period;
generating and outputting a visualization of a personalized dose-response profile for the patient, wherein the visualization of the personalized dose-response profile comprises: (1) a visual representation of a therapeutic profile representing a relationship between seizure control and different dosages of the medication determined based on the first and second seizure data, and (2) a visual representation of a toxicity profile representing a relationship between side effect severity and the different dosages of the medication determined based on the first and second side effect data; and
outputting a treatment recommendation for the patient, wherein the treatment recommendation comprises administering a dose of the medication to the patient to treat the neurological disease or condition, and wherein the dosage is selected based on the personalized dose-response profile.